Abbott, Icos in drug pacts | Chemical & Engineering News
Volume 82 Issue 24 | p. 17 | Concentrates
Issue Date: June 14, 2004

Abbott, Icos in drug pacts

Department: Business

Two antibody development deals were struck last week. In one, Abbott Laboratories will gain access to Protein Design Labs' technology for antibody humanization. Abbott is already a comarketer with MedImmune of the respiratory disease drug Synagis, a humanized antibody that was developed with PDL technology. Separately, Icos has licensed five monoclonal antibody candidates from Raven Biotechnologies. Abbott and Icos will make undisclosed payments to their partners.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment